Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd155-RSV Vaccine in RSV-Seropositive Infants
NCT02927873Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2017
- Primary completion
- Feb 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, single-blind trial of ChAd155-RSV in respiratory syncytial virus infection (RSV) (6 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Any Solicited Local Adverse Events, Number of Subjects With Any Solicited General Adverse Events and 4 more. Started Jan 2017; status: completed.
02
Drugs
ChAd155-RSV
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02927873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927873.